- Home
- LIDR vs PHIO Comparison
LIDR vs PHIO Comparison
Compare LIDR & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- PHIO
- Stock Information
- Founded
- LIDR 2013
- PHIO 2011
- Country
- LIDR United States
- PHIO United States
- Employees
- LIDR N/A
- PHIO N/A
- Industry
- LIDR Auto Parts:O.E.M.
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- LIDR Consumer Discretionary
- PHIO Health Care
- Exchange
- LIDR Nasdaq
- PHIO Nasdaq
- Market Cap
- LIDR 9.8M
- PHIO 8.6M
- IPO Year
- LIDR N/A
- PHIO N/A
- Fundamental
- Price
- LIDR $0.71
- PHIO $2.00
- Analyst Decision
- LIDR Hold
- PHIO Strong Buy
- Analyst Count
- LIDR 1
- PHIO 1
- Target Price
- LIDR N/A
- PHIO $4.00
- AVG Volume (30 Days)
- LIDR 1.2M
- PHIO 875.3K
- Earning Date
- LIDR 05-08-2025
- PHIO 05-15-2025
- Dividend Yield
- LIDR N/A
- PHIO N/A
- EPS Growth
- LIDR N/A
- PHIO N/A
- EPS
- LIDR N/A
- PHIO N/A
- Revenue
- LIDR $246,000.00
- PHIO N/A
- Revenue This Year
- LIDR $2,677.23
- PHIO N/A
- Revenue Next Year
- LIDR $409.09
- PHIO N/A
- P/E Ratio
- LIDR N/A
- PHIO N/A
- Revenue Growth
- LIDR N/A
- PHIO N/A
- 52 Week Low
- LIDR $0.49
- PHIO $0.97
- 52 Week High
- LIDR $4.30
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- LIDR 50.26
- PHIO 54.98
- Support Level
- LIDR $0.71
- PHIO $1.71
- Resistance Level
- LIDR $0.84
- PHIO $2.08
- Average True Range (ATR)
- LIDR 0.06
- PHIO 0.13
- MACD
- LIDR 0.00
- PHIO 0.01
- Stochastic Oscillator
- LIDR 49.61
- PHIO 76.32
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.